Biotechnology The European Commission has granted approval for the label expansion of Kaftrio (ivacaftor/tezacaftor/elexacaftor; marketed in the USA as Trikaftra) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages two through five years old who have at least one F508del mutation in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene, US biopharma Vertex Pharmaceuticals announced today. 23 November 2023